LRMR Projected Dividend Yield
Larimar Therapeutics Inc ( NASDAQ : LRMR )Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. Co.'s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. 21 YEAR PERFORMANCE RESULTS |
LRMR Dividend History Detail LRMR Dividend News LRMR Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |